Alzamend Neuro, Inc. (ALZN): Net Income

Annual figures by period end, from SEC filings.

-$8.77M

Year ended 2026-04-30

-$9.10M

Trailing 12 months to 2026-07-31

2020-04-30 Net Income (USD) 2026-04-30

Period ended	Net Income	Change YoY	Source filing
2026-04-30	-$8.77M	n/m	2026-07-22, From 2025-05-01
2025-04-30	-$4.51M	n/m	2026-07-22, From 2024-05-01
2024-04-30	-$9.95M	n/m	2025-07-22, From 2023-05-01
2023-04-30	-$14.88M	n/m	2024-07-30, From 2022-05-01
2022-04-30	-$12.36M	n/m	2023-07-27, From 2021-05-01
2021-04-30	-$5.05M	n/m	2022-07-19, From 2020-05-01
2020-04-30	-$4.41M	n/a	2021-07-29, From 2019-05-01

Net Income at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Net Income	Change YoY
Alzamend Neuro, Inc. (ALZN)	2026-04-30	-$8.77M	n/m
Inhibitor Therapeutics, Inc. (INTI)	2025-12-31	-$3.30M	n/m
Accustem Sciences Inc. (ACUT)	2025-12-31	-$1.76M	n/m
Artelo Biosciences, Inc. (ARTL)	2025-12-31	-$12.88M	n/m
BullFrog AI Holdings, Inc. (BFRG)	2025-12-31	-$6.50M	n/m
Neonc Technologies Holdings, Inc. (NTHI)	2025-12-31	-$62.15M	n/m
Avenue Therapeutics, Inc. (ATXI)	2025-12-31	-$2.91M	n/m
Alaunos Therapeutics, Inc. (TCRT)	2025-12-31	-$4.18M	n/m
InMed Pharmaceuticals Inc. (INM)	2026-06-30	-$12.56M	n/m

Compare ALZN, INTI, ACUT, ARTL side by side · Screen every company in Pharmaceutical Preparations ↗